Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for priority review the supplemental biologics license application, or sBLA, for Dupixent in a sixth potential indication as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease, or COPD. The target action date for the FDA decision is June 27. Regulatory submissions are under review in China and Europe.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on REGN:
- Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
- Regeneron sees FY24 adjusted EPS $1.42-$1.49, consensus $1.77
- Regeneron announces U.S. FDA accepted priority review for BLA for linvoseltamab
- Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review
- Regeneron, Sanofi announce MHLW in Japan approves Dupixent
